AINDEX
Markets

Valneva SE (VALN)

VALNNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)

$5.57

-0.1650 (-2.88%) today

Closed, Nov 17, 4:00 PM ET

-2.88% 1D
Market cap
$536.10m
P/E
–
EPS, last 4 quarters
$-2.11
Dividend yield
–
Day range
–
52-week range
$4.75 to $12.18
Average volume
–
Previous close
$5.73

Analysts

3 covering

Buy3 buy, 0 hold, 0 sell

Targets a year out average $18.00, +223.5% from here

$18.00now $5.57$18.00

Earnings

next estimate $-0.2300

Next report Nov 24, 2026

Sep 2025

-103.3%

Dec 2025

-223.8%

Mar 2026

-100.0%

Jun 2026

-42.9%

estimate reported, and the surprise

Financials

No quarterly figures from the source.

News

8 latest

The company

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate under regulatory review, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.

Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ-GS
Region
Europe

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.